vs
Side-by-side financial comparison of Alignment Healthcare, Inc. (ALHC) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.2B, roughly 1.9× Alignment Healthcare, Inc.). Zoetis runs the higher net margin — 25.3% vs 0.9%, a 24.3% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs -74.7%). Over the past eight quarters, Alignment Healthcare, Inc.'s revenue compounded faster (34.6% CAGR vs 4.4%).
Alignment Healthcare, Inc. is a U.S.-based healthcare provider offering Medicare Advantage plans for seniors. It adopts a value-based care model, partnering with local providers to deliver personalized coordinated medical services, prescription drug coverage and supplemental benefits to members across multiple U.S. states.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
ALHC vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $2.4B |
| Net Profit | $11.4M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | — | 31.9% |
| Net Margin | 0.9% | 25.3% |
| Revenue YoY | -74.7% | 3.0% |
| Net Profit YoY | — | 3.8% |
| EPS (diluted) | — | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.0B | $2.4B | ||
| Q3 25 | $993.7M | $2.4B | ||
| Q2 25 | $1.0B | $2.5B | ||
| Q1 25 | $926.9M | $2.2B | ||
| Q4 24 | $701.2M | $2.3B | ||
| Q3 24 | $692.4M | $2.4B | ||
| Q2 24 | $681.3M | $2.4B |
| Q1 26 | $11.4M | — | ||
| Q4 25 | $-11.0M | $603.0M | ||
| Q3 25 | $3.7M | $721.0M | ||
| Q2 25 | $15.7M | $718.0M | ||
| Q1 25 | $-9.1M | $631.0M | ||
| Q4 24 | $-31.1M | $581.0M | ||
| Q3 24 | $-26.4M | $682.0M | ||
| Q2 24 | $-24.0M | $624.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% |
| Q1 26 | — | — | ||
| Q4 25 | -1.0% | 31.9% | ||
| Q3 25 | 0.8% | 37.0% | ||
| Q2 25 | 2.2% | 36.7% | ||
| Q1 25 | -0.6% | 36.5% | ||
| Q4 24 | -3.2% | 31.6% | ||
| Q3 24 | -2.8% | 36.6% | ||
| Q2 24 | -2.7% | 33.0% |
| Q1 26 | 0.9% | — | ||
| Q4 25 | -1.1% | 25.3% | ||
| Q3 25 | 0.4% | 30.0% | ||
| Q2 25 | 1.5% | 29.2% | ||
| Q1 25 | -1.0% | 28.4% | ||
| Q4 24 | -4.4% | 25.1% | ||
| Q3 24 | -3.8% | 28.6% | ||
| Q2 24 | -3.5% | 26.4% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.04 | $1.37 | ||
| Q3 25 | $0.02 | $1.63 | ||
| Q2 25 | $0.07 | $1.61 | ||
| Q1 25 | $-0.05 | $1.41 | ||
| Q4 24 | $-0.15 | $1.29 | ||
| Q3 24 | $-0.14 | $1.50 | ||
| Q2 24 | $-0.13 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $705.6M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $206.9M | $3.3B |
| Total Assets | $1.3B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $705.6M | — | ||
| Q4 25 | $604.2M | — | ||
| Q3 25 | $644.1M | $2.1B | ||
| Q2 25 | $503.8M | $1.4B | ||
| Q1 25 | $479.5M | $1.7B | ||
| Q4 24 | $470.6M | $2.0B | ||
| Q3 24 | $381.0M | $1.7B | ||
| Q2 24 | $363.7M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | $323.2M | — | ||
| Q3 25 | $322.7M | — | ||
| Q2 25 | $322.3M | — | ||
| Q1 25 | $321.9M | — | ||
| Q4 24 | $321.4M | — | ||
| Q3 24 | $212.0M | — | ||
| Q2 24 | $211.7M | — |
| Q1 26 | $206.9M | — | ||
| Q4 25 | $179.3M | $3.3B | ||
| Q3 25 | $161.9M | $5.4B | ||
| Q2 25 | $141.0M | $5.0B | ||
| Q1 25 | $108.1M | $4.7B | ||
| Q4 24 | $99.9M | $4.8B | ||
| Q3 24 | $114.5M | $5.2B | ||
| Q2 24 | $123.7M | $5.0B |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.1B | $15.5B | ||
| Q3 25 | $1.1B | $15.2B | ||
| Q2 25 | $1.0B | $14.5B | ||
| Q1 25 | $895.6M | $14.1B | ||
| Q4 24 | $782.1M | $14.2B | ||
| Q3 24 | $692.3M | $14.4B | ||
| Q2 24 | $716.3M | $14.2B |
| Q1 26 | — | — | ||
| Q4 25 | 1.80× | — | ||
| Q3 25 | 1.99× | — | ||
| Q2 25 | 2.29× | — | ||
| Q1 25 | 2.98× | — | ||
| Q4 24 | 3.22× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.71× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $128.7M | $893.0M |
| Free Cash FlowOCF − Capex | — | $732.0M |
| FCF MarginFCF / Revenue | — | 30.7% |
| Capex IntensityCapex / Revenue | — | 6.7% |
| Cash ConversionOCF / Net Profit | 11.27× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $128.7M | — | ||
| Q4 25 | $-50.4M | $893.0M | ||
| Q3 25 | $144.6M | $938.0M | ||
| Q2 25 | $29.1M | $486.0M | ||
| Q1 25 | $16.6M | $587.0M | ||
| Q4 24 | $-8.7M | $905.0M | ||
| Q3 24 | $26.2M | $951.0M | ||
| Q2 24 | $23.5M | $502.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-55.4M | $732.0M | ||
| Q3 25 | $139.1M | $805.0M | ||
| Q2 25 | $21.1M | $308.0M | ||
| Q1 25 | $8.4M | $438.0M | ||
| Q4 24 | $-18.0M | $689.0M | ||
| Q3 24 | $16.9M | $784.0M | ||
| Q2 24 | $11.8M | $370.0M |
| Q1 26 | — | — | ||
| Q4 25 | -5.5% | 30.7% | ||
| Q3 25 | 14.0% | 33.5% | ||
| Q2 25 | 2.1% | 12.5% | ||
| Q1 25 | 0.9% | 19.7% | ||
| Q4 24 | -2.6% | 29.7% | ||
| Q3 24 | 2.4% | 32.8% | ||
| Q2 24 | 1.7% | 15.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 6.7% | ||
| Q3 25 | 0.6% | 5.5% | ||
| Q2 25 | 0.8% | 7.2% | ||
| Q1 25 | 0.9% | 6.7% | ||
| Q4 24 | 1.3% | 9.3% | ||
| Q3 24 | 1.3% | 7.0% | ||
| Q2 24 | 1.7% | 5.6% |
| Q1 26 | 11.27× | — | ||
| Q4 25 | — | 1.48× | ||
| Q3 25 | 38.77× | 1.30× | ||
| Q2 25 | 1.86× | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | — | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALHC
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
